general

Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib – A phase II trial (PEMRAD).

 150 150 admciia
By:
0

Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib – A phase II trial (PEMRAD).

O’Kane GM, Mesci A, Jang RW, Barry A, Bocaya CM, Boukhaled GM, Acton H, Doddington D, Rodrigo R, Chan LML, Noamani B, Harvey H, Elia A, Law R, Prince R, Doherty M, Dodd A, Wong DK, Wang L, Wang BX, Chen EX, Dawson LA, Knox JJ.
JHEP Rep. 2025 Nov 1;8(2):101658.

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial

 150 150 admciia
By:
0

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial

Rose AAN, Maxwell J, Rousselle E, Mukonoweshuro CL, Elkholi IE, Riaud M, Biondini M, Cianfarano E, Soria-Bretones I, Tobin C, McGuire M, Law RWY, Elia AJ, Wang BX, King I, Zhang T, Pugh TJ, Kamil ZS, Butler M, Shepherd FA, Leighl NB, Razak AA, Hansen A, Saibil SD, Bedard PL, Siegel PM, Siu LL, Cescon DW, Spreafico A.
Nat Commun. 2026 Jan 3;17(1):1323.

Cross-Cancer Analysis Reveals a Distinct Pattern of Immune Modulation During Curative Radiation Therapy

 150 150 admciia
By:
0
Cross-Cancer Analysis Reveals a Distinct Pattern of Immune Modulation During Curative Radiation Therapy

Said BI, Boukhaled GM, Lok BH, Lukovic J, Mesci A, Waldron J, Wong P, Wang BX, Brooks DG, Milosevic M.
Int J Radiat Oncol Biol Phys. 2026 Feb 1;124(2):441-450.

CD28-driven ex vivo generation of stem-like memory CD8+ T cells bypassing CD3/TCR signaling

 150 150 admciia
By:
0
CD28-driven ex vivo generation of stem-like memory CD8+ T cells bypassing CD3/TCR signaling.

Ihara F, Ohashi Y, Zheng EYF, Fukao S, Rodrigo R, Noamani B, Boukhaled GM, Wang BX, Han DH, Wei X, Burt BD, Saso K, Matsunaga Y, Ly D, Kagoya Y, Butler MO, Mak TW, Saibil SD, Hirano N.
Proc Natl Acad Sci U S A. 2026 Apr 28;123(17):e2524626123.